Tania Payo-Serafín

6PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 19, 2026
Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients.

|Feb 03, 2025
Correction: Fondevila et al. Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Cancers 2021, 13, 5349.

Flavia Fondevila, Paula Fernández-Palanca, Carolina Méndez-Blanco

|May 28, 2024
Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Tania Payo-Serafín, Carolina Méndez-Blanco, Paula Fernández-Palanca

|Jul 27, 2022
Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies.

Paula Fernández-Palanca, Tania Payo-Serafín, Flavia Fondevila

|Nov 13, 2021
Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis.

Flavia Fondevila, Paula Fernández-Palanca, Carolina Méndez-Blanco

|Nov 13, 2021
Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.

Flavia Fondevila, Carolina Méndez-Blanco, Paula Fernández-Palanca

Pageof 1

Frequent Collaborators

5 joint publications

Carolina Méndez-Blanco

5 joint publications

Paula Fernández-Palanca

5 joint publications

Javier González-Gallego

5 joint publications

José L Mauriz